Why LDL Won the Cholesterol Wars

Why LDL Won the Cholesterol Wars

The 2026 ACC/AHA Dyslipidemia Guideline replaces the 2018 framework, restores explicit LDL-C targets, and tightens thresholds for high-risk patients. Three landmark trials this cycle reshape what's possible: Ez-PAVE proves <55 mg/dL beats <70 mg/dL in secondary prevention. VESALIUS-CV extends PCSK9 benefit upstream into primary prevention. CORALreef Lipids and AddOn deliver the first oral PCSK9 inhibitor — and head-to-head, it crushes every existing oral non-statin therapy. This episode covers all of it, plus a clinician's playbook for answering statin denialism in the room. No noise. Just substance --- I am tired of watching people die preventable deaths because someone on the internet convinced them that statins are a pharmaceutical conspiracy, that LDL cholesterol doesn't cause heart disease, or that their body "needs" high cholesterol to function. These are not heterodox scientific positions. They are misinformation — and in my clinical world, misinformation has a body count. This week on Substance Over Noise: the 2026 ACC/AHA Dyslipidemia Guideline, the Ez-PAVE head-to-head target trial, VESALIUS-CV upstream primary prevention data, and the world's first oral PCSK9 inhibitor to pass Phase 3. The science on LDL is not just settled — it is accelerating. The deniers didn't get the memo. Allow me to deliver it. WHAT WE COVER: → Why LDL-C (and ApoB) is causal, not correlative — the CTT Collaboration's 170,000-patient meta-analysis, the 2017 EAS Bradford-Hill consensus, and the Mendelian randomization data showing cumulative lifetime LDL exposure compounds risk threefold. → The 2026 ACC/AHA Dyslipidemia Guideline — what changed, why explicit numeric targets are back, and how the new therapeutic cascade (statin → ezetimibe → PCSK9 inhibitor → bempedoic acid → inclisiran) fits together. → Ez-PAVE — the first head-to-head RCT comparing LDL-C targets in secondary prevention. <55 mg/dL beat <70 mg/dL by 33% in 3-year MACE (HR 0.67, P=0.002). The inferential burden is gone. → VESALIUS-CV subgroup analysis — evolocumab cuts MACE by 31% in primary prevention patients with diabetes and no known atherosclerosis. The wall between primary and secondary prevention is more permeable than the guidelines acknowledge. → CORALreef Lipids — enlicitide, the first oral PCSK9 inhibitor, drops LDL-C 57% on top of statin background. Same magnitude as injectables. Different delivery. That changes everything. → CORALreef AddOn (NEW from ACC.26) — head-to-head against bempedoic acid, ezetimibe, and BA+EZE. Enlicitide wins by 28–57 percentage points. 78% reach <55 mg/dL versus 20% on the current best oral combination. The Lp(a) data is the kicker. → A clinician's playbook for answering statin denialism — the muscle-damage argument, the surrogate-endpoint argument, the cholesterol-for-my-brain argument, the supplement argument. With the 2026 Novak et al. real-world data showing statin use associated with 31% lower incident Alzheimer's risk across 838,000 matched patients. → Six things to do Monday morning: measure Lp(a) on every adult, treat established ASCVD to <55 mg/dL, use CAC scoring for borderline patients, consider PCSK9 inhibition early in high-risk diabetes, intensify lipid therapy before ACS discharge, and start treating early because every untreated year is one you cannot undo. The guidelines are the most actionable in a decade. The tools exist. The evidence is settled. What remains is clinical will — and the discipline to not let misinformation stand between our patients and the treatments that will save their lives. Read the full article with figures, citations, and tables: substance-over-noise.beehiiv.com/p/the-cholesterol-wars-are-over-ldl-won [https://substance-over-noise.beehiiv.com/p/the-cholesterol-wars-are-over-ldl-won] DISCLOSURE: The author is co-founder and Chief Medical Officer of Accomplish Health, a telehealth platform providing obesity medicine and medical bariatric care. This newsletter reflects his independent clinical perspective and is intended for educational purposes. It does not constitute medical advice and should not be used to guide individual patient care without consultation with a qualified clinician. No pharmaceutical industry compensation was received in connection with this piece. The CORALreef Lipids trial was funded by MSD (Merck). Enlicitide decanoate has not yet received FDA approval as of publication. Subscribe to Substance Over Noise: substance-over-noise.beehiiv.com [https://substance-over-noise.beehiiv.com] Follow on X: @MichaelAlbertMD KEY TRIALS & PAPERS DISCUSSED * 2026 ACC/AHA Dyslipidemia Guideline — Blumenthal et al. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423 * Ez-PAVE Trial — Lee YJ et al. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2600283 * VESALIUS-CV Subgroup — Marston NA et al. JAMA. 2026. DOI: 10.1001/jama.2026.3277 * CORALreef Lipids — Navar AM et al. N Engl J Med. 2026;394:529–539. DOI: 10.1056/NEJMoa2511002 * CORALreef AddOn — Catapano AL et al. Presented at ACC.26, March 2026. * CTT Collaboration Meta-Analysis — Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5 * Ference 2017 EAS Consensus — Eur Heart J. 2017;38:2459–2472. DOI: 10.1093/eurheartj/ehx144 * EBBINGHAUS-OLE (PCSK9 cognitive safety) — Zimerman A et al. NEJM Evid. 2025;4(1). DOI: 10.1056/EVIDoa2400112 * Novak 2026 (Statins & Alzheimer's) — J Alzheimers Dis. 2026;110(3):1474–1489. DOI: 10.1177/13872877261424220 * CLEAR Outcomes (Bempedoic Acid) — Nissen SE et al. N Engl J Med. 2023;388:1353–1364. DOI: 10.1056/NEJMoa2215024 * 2025 ESC/EAS Focused Update — Mach F et al. Eur Heart J. 2025;46:4359–4378. DOI: 10.1093/eurheartj/ehaf190 * SPORT Trial (Statins vs. Supplements) — Laffin LJ et al. J Am Coll Cardiol. 2023;81(1):1–12.

The Dangerous Reality of Peptide Biohacking

🎙️ SHOW NOTES The Dangerous Reality of Peptide Biohacking Substance Over Noise | Episode 1 EPISODE SUMMARY A highly educated patient walks into a clinic. Her coronary calcium score is 280. Her LDL is 168. Her father died of a heart attack at 58. She just threw her statin in the trash because of a forum post — and she's currently injecting a synthetic compound studied in exactly 14 human beings into her thigh three times a week. That contradiction is where this episode begins. In this deep dive, I break down the exploding, largely unregulated world of peptide biohacking — separating genuine science from grey-market hype and examining the intense political battles over medical freedom that are actively rewriting the rules of healthcare right now. We start with the real biology: what peptides actually are, why some of the most important drugs in history (insulin, GLP-1 agonists) are peptides, and what the genuine scientific discovery of mitochondria-derived microproteins by Dr. Pinchas Cohen at USC actually revealed. Then we follow the thread from legitimate science to grey market explosion — tracing how compounds like BPC-157, MOTS-c, Melanotan II, and TB-500 went from obscure lab findings to refrigerators across America, despite having almost no human clinical data behind them. We examine the FDA's Category 2 "Do Not Compound" list of 17 peptides, run through the actual evidence behind each one (spoiler: it mostly isn't there), and investigate what independent mass spectrometry testing found when a journalist bought grey market peptides online — including heavy metal contamination, endotoxins from unsterile labs, and active ingredients at less than half the advertised concentration. Then we get to the harder question: why are intelligent, health-conscious people doing this? The answer isn't stupidity. It's a rational response to a medical system that genuinely failed them — the opioid crisis, institutional capture, profit-driven medicine. The tragedy is that the escape route they've chosen has the same financial incentives and none of the guardrails. This episode doesn't end with easy answers. It ends with a question worth sitting with: are we biohacking to genuinely feel better, or because our culture refuses to let us be human? Key Clinical Takeaways * BPC-157 has approximately 30 human subjects in the entire published literature. 35 of 36 studies are pre-clinical. A 2015 Phase 1 trial in 42 volunteers was registered, then quietly canceled with no results ever published. * AOD-9604 completed a rigorous Phase 2b/3 trial of 900+ subjects and showed no significant weight loss versus placebo. The pharmaceutical company abandoned it. It is now widely sold online as a fat-loss peptide. * Melanotan II is a non-selective melanocortin agonist that activates the same cellular pathway as UV radiation. Multiple dermatological case reports link systemic injection to rapid melanoma progression in patients with atypical moles. * MOTS-c showed promising results in aged mouse models, but its Phase 1 trial collapsed due to an impractically short half-life. It now sits on the FDA restricted list. * TB-500 is a synthetic fragment of Thymosin beta-4 — not the parent molecule. There are zero published human trials. WADA has banned it under the growth factor category. Its safety profile in humans is entirely unknown. * BPC-157 and angiogenesis — BPC-157 is a potent stimulator of new blood vessel formation in pre-clinical models. When injected systemically, it cannot distinguish between a healing tendon and a dormant microtumor. The mechanism that repairs tissue may simultaneously supply a vascular network to feed a cancer. * Grey market purity — Independent mass spectrometry testing found that roughly 10% of grey market peptide samples have severe anomalies. Vials purchased by a journalist contained lead, endotoxins from unsterile manufacturing, and active ingredients at less than 42% of the advertised concentration. * The statin nocebo effect — A Lancet meta-analysis of ~124,000 patients found that 62 of 66 claimed statin side effects were unsupported by clinical data. Patients in blinded trials reported identical muscle aches on sugar pills as on statins. The symptom burden is psychologically generated by the expectation of harm. * The trust paradox — Public skepticism of institutional medicine is rational. The opioid crisis proved that financial incentives can fatally distort clinical practice. The tragedy is that the alternative — wellness influencers and grey-market vendors — offers identical financial incentives with none of the regulatory guardrails. SOURCES CITED IN THIS EPISODE 1. PBS News (March 2026) — FDA public meeting on peptide reclassification and the MAHA movement 2. STAT News — Op-ed by Dr. Vikas Patel on the epistemology of medical trust and institutional failure 3. The New Yorker — Investigative report on peptide labs, grey market clinics, and the biohacking subculture (includes reporting on Dr. Pinchas Cohen, Dr. Craig Conover, Dr. Edwin Lee, and the Las Vegas convention incident) 4. Michael Albert, MD — The Peptide Wild West, Parts I & II, Substance Over Noise newsletter (substance-over-noise.beehiiv.com [https://substance-over-noise.beehiiv.com]) 5. Krous Analytical, Texas — Independent mass spectrometry testing of grey market peptide vials 6. Lancet — Meta-analysis of statin adverse effects across ~124,000 patients 7. SURMOUNT-4 / STEP-10 trials — Referenced for context on legitimate GLP-1 pharmacology PEOPLE AND CONCEPTS MENTIONED Scientists & Clinicians * Dr. Pinchas Cohen (USC) — Discoverer of Humanin and MOTS-c; pioneer of mitochondria-derived peptide research * Predrag Sikiric (Croatia) — Discoverer of BPC-157; isolated from human gastric juice in the 1990s * Dr. Vikas Patel — Author of the STAT News op-ed on trust, epistemology, and institutional failure * Dr. Craig Conover (Charleston, SC) — Concierge MD; featured in The New Yorker for peptide and methylene blue IV protocols * Dr. Edwin Lee (Orlando, FL) — Endocrinologist; co-founder of the Clinical Peptide Society * Frances Kelsey — FDA inspector who blocked Thalidomide approval in the US * Luke Turnock — Sociologist who coined the term "folk pharmacology" to describe internet-driven, decentralized self-experimentation with unapproved compounds Regulatory & Political Context * DSHEA (1994) — Dietary Supplement Health and Education Act; inverted the burden of proof for supplement safety * FDA Category 2 list — 17 peptides banned from compounding due to lack of human safety data * MAHA movement — Make America Healthy Again; pushing to move 14 of 17 peptides back to Category 1 * Natural Products Association — Supplement industry lobbying group petitioning the FDA * Elixir Sulfanilamide (1937) — Antibiotic dissolved in antifreeze; killed 100+ people; led to the 1938 Food, Drug, and Cosmetic Act * Thalidomide — Morning sickness drug causing 10,000+ birth defects; led to the 1962 Kefauver Harris Amendment Key Compounds Discussed * BPC-157, MOTS-c, Humanin, AOD-9604, Melanotan II, TB-500, KPV, Retatrutide, Methylene blue, PT-141 READ THE FULL WRITTEN BREAKDOWN This episode is based on my two-part newsletter series, The Peptide Wild West. If you want the citations, the receptor pharmacology, and the full clinical evidence review, it's all there. 📖 Read it at substance-over-noise.beehiiv.com [https://substance-over-noise.beehiiv.com] FOLLOW SUBSTANCE OVER NOISE * Newsletter: substance-over-noise.beehiiv.com [https://substance-over-noise.beehiiv.com] * Website: michaelalbertmd.com [https://michaelalbertmd.com] * X / Twitter: @MichaelAlbertMD * LinkedIn: Michael Albert, MD Written by Michael Albert, MD. Audio generated by AI — and I'm transparent about that, because transparency is what this show is built on. Substance Over Noise is for informational purposes only and does not constitute medical advice. Always consult your physician before starting, stopping, or changing any medication or supplement.